Antipsychotic drugs and obesity
- 28 February 2011
- journal article
- review article
- Published by Elsevier BV in Trends in Molecular Medicine
- Vol. 17 (2), 97-107
- https://doi.org/10.1016/j.molmed.2010.10.010
Abstract
No abstract availableKeywords
This publication has 68 references indexed in Scilit:
- Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia PatientsNeuropsychopharmacology, 2010
- Effectiveness of Medications Used to Attenuate Antipsychotic-Related Weight Gain and Metabolic Abnormalities: A Systematic Review and Meta-AnalysisNeuropsychopharmacology, 2010
- Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugsMolecular Psychiatry, 2010
- A Common Polymorphism in the Cannabinoid Receptor 1 (CNR1) Gene is Associated with Antipsychotic-Induced Weight Gain in SchizophreniaNeuropsychopharmacology, 2010
- Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and AdolescentsPublished by American Medical Association (AMA) ,2009
- Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)European Psychiatry, 2009
- Low dopamine striatal D2 receptors are associated with prefrontal metabolism in obese subjects: Possible contributing factorsNeuroImage, 2008
- Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectinSchizophrenia Research, 2008
- Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: One-year analysisSchizophrenia Research, 2007
- Deletion of the serotonin 2c receptor from transgenic mice overexpressing leptin does not affect their lipodystrophy but exacerbates their diet-induced obesityBiochemical and Biophysical Research Communications, 2006